Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia

Tachycardia, Ventricular Clinical Trial

— CEASE-VT  

Official title:

Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia: A Multi-center Randomized Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01097330
• Other study ID #: CEASE-VT
• Status: Terminated
• Phase: Phase 3
• Start date: August 2010
• Est. completion date: March 2012

Study information

• Verified date: January 2020
• Source: Population Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Implantable Cardioverter Defibrillators (ICDs) provide a shock or pacing therapy to bring back a normal heart beat when a patient experiences a dangerous abnormal heart rhythm such as ventricular tachycardia (VT). ICDs are very successful in bringing back a normal heart beat when VT occurs, but they do not prevent further dangerous heart rhythms from occurring. This study is designed to determine the best way to manage patients who have an ICD and who continue to have episodes of VT. There are two methods for treatment the VT: 1) Ablation, and 2) Medication.

An ablation procedure involves placing a flexible catheter (insulated wire) in the groin area and threading it into the heart. After the doctor has located the affected area responsible for the VT, radiofrequency energy is delivered by the power generator through the catheter to the inside of the heart. The radiofrequency energy ablates (burns) a small area of the heart tissue thought to cause the VT.

A medication called Amiodarone is an "anti-arrhythmic" prescribed to prevent abnormal heart rhythms from recurring.

The purpose of this study is to compare these two different methods for treating VT. Treatment with ablation and amiodarone are both considered the standard of care for patients with VT but they have not been compared directly in a study like this before.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 84 Years

Eligibility

Inclusion Criteria - Patients must meet all of the following criteria:

• > 18 and < 85 years of age

• ICD implanted for primary prophylaxis against sudden cardiac death or ICD implanted for secondary prophylaxis against spontaneous or inducible sustained VT without any reversible causes

• Coronary artery disease (CAD) with prior myocardial infarction (MI)

• ICD or electrocardiogram (ECG) documentation of ventricular arrhythmia responsible for appropriate ICD therapy [antitachycardia pacing (ATP) & shocks].

Exclusion Criteria - Patients should not have any of the following criteria:

• Contraindication or allergy to contrast media, routine procedural medications or catheter materials

• Contraindication to an interventional procedure

• Current or previous (within 3 months) amiodarone therapy

• Atrial Fibrillation requiring antiarrhythmic drug therapy

• Contraindication to amiodarone therapy

• New York Heart Association (NYHA) functional class IV

• Myocardial infarction within the past 60 days

• Stroke within the past 90 days

• Unstable angina

• Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or long QT syndrome

• Patients with active ischemia that are eligible for revascularization

• Life expectancy less than 6 months

• Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation

• Untreated hypothyroidism or hyperthyroidism. Patients who are euthyroid on thyroid hormone replacement therapy are acceptable.

• Current enrollment in another investigational drug or device study.

• Presence of any other condition that the investigator feels would be problematic or would restrict or limit the participation of the patient for the entire study period.

• Absolute contra-indication to the use of heparin and or warfarin.

• Documented intra-atrial thrombus, ventricular thrombus (< 6 months after detection of thrombus), tumor, or another abnormality which precludes catheter introduction.

• Females of childbearing potential who are not practicing protocol acceptable method of birth control.

Related Conditions & MeSH terms

• Defibrillators, Implantable
• Tachycardia
• Tachycardia, Ventricular

Intervention

Procedure:
• Ablation
Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization

Drug:
• Amiodarone
Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study

Locations

Country	Name	City	State
Canada	Hamilton Health Sciences	Hamilton	Ontario
Canada	McGill University Health Center	Montreal	Quebec
Canada	Southlake Regional Health Centre	Newmarket	Ontario
Canada	University of Ottawa Heart Institute	Ottawa	Ontario
Canada	Institut Universitaire de Cardiologie et Pneumologie de Québec	Quebec
China	Beijng Fuwai Heart Hospital	Beijing
United States	Texas Cardiac Arrhythmia Research Foundation	Austin	Texas
United States	University of Virginia Health System	Charlottesville	Virginia
United States	Northwestern University	Chicago	Illinois
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (3)

Lead Sponsor	Collaborator
Population Health Research Institute	Abbott Medical Devices, Hamilton Health Sciences Corporation

Countries where clinical trial is conducted

United States,  Canada,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Appropriate ICD Therapy, Slow VT or Sudden Cardiac Death	Number of participants with a composite outcome of any of: Appropriate Implantable Cardioverter Defibrillator (ICD) therapy [Including antitachycardia pacing (ATP) and shocks]; Slow ventricular tachycardia (VT) below ICD detection threshold leading to hospitalization or necessitates antiarrhythmic medications and/or catheter ablation; Sudden Cardiac Death	From 30 days following randomization until final follow-up visit
Secondary	Number of Participants With (a) Ablation or Amiodarone Complications, (b) Inappropriate Shocks From ICD, or (c) Need for Concomitant Use of Sotalol, Dofetilide, Azimilide or Class 1 Antiarrhythmic Agents in Either Arm of the Trial.	Number of Participants with (a) Ablation or Amiodarone Complications, (b) Inappropriate Shocks from ICD, or (c) Need for Concomitant use of Sotalol, Dofetilide, Azimilide or Class 1 Antiarrhythmic agents in either arm of the trial.	from randomization until final follow-up
Secondary	Quality of Life Score	Quality of life score in each treatment arm using the EQ-5D Visual Analogue Scale (VAS) (euroqol.org). The EQ-5D VAS is a patient reported scale from 0 to 100 on which the patient rates how good or bad their health is today with 100 being the best health they can imagine and 0 being the worst health they can imagine.	At 6 months follow-up

External Links

•   Population Health Research Institute